ReviewPaediatric drugs2021
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
Review in Paediatric drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2025Pooled it
- SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.Frontiers in immunology · 2026Trial
- The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.Archives of dermatological research · 2025Trial
- Possible effects of anti-interleukin-17 agents on erythrodermic psoriasis with thymoma: A case report.JAAD case reports · 2025Article
- Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report.Frontiers in medicine · 2025Article
- TBrain, behavior, and immunity · 2025Article
- Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population.Einstein (Sao Paulo, Brazil) · 2024Article
- Case report: Intralesional secukinumab injection for pediatric nail psoriasis: does it have to be a positive outcome?Frontiers in immunology · 2024Article
- The Current Advancement in Psoriasis.Cureus · 2023Review
- Therapeutic Antibodies in Medicine.Molecules (Basel, Switzerland) · 2023Review
- Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability.Patient preference and adherence · 2023Review
- Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.Dermatologic therapy · 2022Article
- A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group.Frontiers in medicine · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous secukinumab (Cosentyx
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.